Previous 10 | Next 10 |
ESSA Pharma to Present at the Jefferies London Healthcare Conference Canada NewsWire SOUTH SAN FRANCISCO , Calif. and VANCOUVER, Canada , Nov. 8, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutica...
2023-11-07 19:06:24 ET Summary A phase 2 study is being advanced using EPI-7386 in combination with enzalutamide to treat patients with metastatic castration-resistant prostate cancer; Positive updated PSA data presented at medical conference. EPI-7386 is being advanced as a monot...
2023-11-07 09:23:48 ET More on ESSA Pharma Seeking Alpha’s Quant Rating on ESSA Pharma Historical earnings data for ESSA Pharma Financial information for ESSA Pharma For further details see: ESSA Pharma enters into at-the-market equity offering sal...
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat Canada NewsWire Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in pat...
2023-10-24 11:23:00 ET Summary Ambrx Biopharma Inc. common stock experienced an irrational selloff following the Phase 1/2 ESMO data release for its ADC candidate ARX517, presenting a buying opportunity. The company's technology for next-generation ADCs has shown safety benefits a...
2023-10-23 10:00:15 ET Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector as earnings close in For further details see: ImmunityBio, Palatin Technologies among healthcare movers
2023-10-23 08:31:36 ET Losers: Revolution Medicines ( RVMD ) -31% . Troika Media Group ( TRKA ) -21% . Li-Cycle Holdings Corp ( LICY ) -21% announces review of the rochester hub project . Mmtec ( MTC ) -18% . Palatin Technologies ( ...
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress Canada NewsWire Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients w...
2023-10-16 08:30:08 ET PCTEL ( NASDAQ: PCTI ) +48% . Essa Pharma ( EPIX ) +32% . Almacenes Exito ( EXTO ) +32% . Ambrx Biopharma ( AMAM ) +32% Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX5...
2023-09-19 17:05:50 ET More on ESSA Pharma Seeking Alpha’s Quant Rating on ESSA Pharma Historical earnings data for ESSA Pharma Financial information for ESSA Pharma For further details see: ESSA Pharma files for $200M mixed shelf offering - filing
News, Short Squeeze, Breakout and More Instantly...
ESSA Pharma Inc. Company Name:
EPIX Stock Symbol:
NASDAQ Market:
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024 Canada NewsWire Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in ...
ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference Canada NewsWire SOUTH SAN FRANCISCO , Calif. and VANCOUVER, BC , April 9, 2...
2024-03-27 01:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...